Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.

Acta orthopaedica Scandinavica. Supplementum Pub Date : 2004-04-01 DOI:10.1080/00016470410001708360

J O Fernberg, K Sundby Hall

{"title":"Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.","authors":"J O Fernberg, K Sundby Hall","doi":"10.1080/00016470410001708360","DOIUrl":null,"url":null,"abstract":"<p><p>The Scandinavian Sarcoma Group (SSG) started its first chemotherapy study in soft tissue sarcoma (STS) in 1981 (SSG I). This study evaluated single agent doxorubicin given adjuvant in a prospective randomized trial in patients with high-grade STS. Neither overall survival nor disease-free survival was improved. Combination chemotherapy was hereafter studied in a phase II study (1991-1994) combining ifosfamide and continuous infusion etoposide with growth factor support (SSG X). The response rate in previously untreated patients was high (42%), but complete remissions were few. Analysis made on patients operated after chemotherapy indicated improved survival in this subgroup. Meta-analyses of adjuvant chemotherapy for localised resectable STS in adults, including the SSG I trial, has indicated improved disease-free survival and a trend towards improved overall survival. Presently, SSG is testing whether such a benefit can be found for adjuvant ifosfamide and doxorubicin treatment given after primary surgery in selected patients with high-grade STS and other well defined unfavourable prognostic factors (SSG XIII).</p>","PeriodicalId":75404,"journal":{"name":"Acta orthopaedica Scandinavica. Supplementum","volume":"75 311","pages":"77-86"},"PeriodicalIF":0.0000,"publicationDate":"2004-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/00016470410001708360","citationCount":"21","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta orthopaedica Scandinavica. Supplementum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/00016470410001708360","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 21

Abstract

The Scandinavian Sarcoma Group (SSG) started its first chemotherapy study in soft tissue sarcoma (STS) in 1981 (SSG I). This study evaluated single agent doxorubicin given adjuvant in a prospective randomized trial in patients with high-grade STS. Neither overall survival nor disease-free survival was improved. Combination chemotherapy was hereafter studied in a phase II study (1991-1994) combining ifosfamide and continuous infusion etoposide with growth factor support (SSG X). The response rate in previously untreated patients was high (42%), but complete remissions were few. Analysis made on patients operated after chemotherapy indicated improved survival in this subgroup. Meta-analyses of adjuvant chemotherapy for localised resectable STS in adults, including the SSG I trial, has indicated improved disease-free survival and a trend towards improved overall survival. Presently, SSG is testing whether such a benefit can be found for adjuvant ifosfamide and doxorubicin treatment given after primary surgery in selected patients with high-grade STS and other well defined unfavourable prognostic factors (SSG XIII).

查看原文本刊更多论文

软组织肉瘤的化疗。斯堪的纳维亚肉瘤集团的经验。

斯堪的纳维亚肉瘤组(SSG)于1981年开始了对软组织肉瘤(STS)的首个化疗研究(SSG I)，该研究在一项前瞻性随机试验中评估了单药阿霉素对高度STS患者的辅助治疗。总生存期和无病生存期均未改善。此后，在一项II期研究(1991-1994)中，研究了异环磷酰胺和持续输注依托泊苷联合生长因子支持(SSG X)的联合化疗。先前未经治疗的患者的缓解率很高(42%)，但完全缓解的患者很少。对化疗后手术患者的分析表明，该亚组生存率提高。包括SSG I试验在内的成人局部可切除STS辅助化疗的荟萃分析表明，无病生存期和总生存期有改善的趋势。目前，SSG正在测试是否可以在原发性手术后对具有高度STS和其他明确的不良预后因素的患者给予异环磷酰胺和阿霉素辅助治疗的获益(SSG XIII)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta orthopaedica Scandinavica. Supplementum

自引率

0.00%

发文量